Chemistry:Lucatumumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD40 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Molar mass | 146 kg/mol |
  (what is this?) (verify) | |
Lucatumumab (CHIR 12.12 or HCD122)[1] is a human monoclonal antibody against CD40[2] development of which was discontinued by Novartis in 2013 after it was investigated for the treatment of various types of cancer like multiple myeloma and follicular lymphoma.[3]
It is an antagonist to CD40 that was created by scientists at Chiron using Abgenix' XenoMouse transgenic mouse to generate fully human antibodies.[4][5] It was made part of the collaboration between Chiron and Xoma that the companies commenced in 2004.[6][7][8] Novartis took over the project when it acquired Chiron in 2005.[9][10]
In in vitro studies, it inhibited cell proliferation induced by CD40 ligands and induced cell lysis.[11]
Over three Phase 1 trials in multiple myeloma and chronic lymphocytic leukemia, the companies made an effort to determine the optimal dose, and obtained unclear results.[1] The Phase I part of a planned Phase I/II trial in multiple myeloma was started in 2005, and in 2012 was updated to Phase II and closed; as of 2014 the results had not been published.[1]
References
- ↑ 1.0 1.1 1.2 "Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials". Immunopharmacology and Immunotoxicology 36 (2): 96–104. April 2014. doi:10.3109/08923973.2014.890626. PMID 24555495.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council – Lucatumumab, American Medical Association.
- ↑ "Lucatumumab" (in en). AdisInsight. http://adisinsight.springer.com/drugs/800013077.
- ↑ "Press release: XOMA and Chiron Announce Preclinical Data Presentations on CHIR-12.12 at American Hematology Conference" (in en). XOMA and Chiron vis Businesswire. December 2, 2004. http://www.businesswire.com/news/home/20041202005701/en/XOMA-Chiron-Announce-Preclinical-Data-Presentations-CHIR-12.12.
- ↑ "(Poster Session No. 627-II) A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma." (in en). Blood 104 (11): 3279. 16 November 2004. doi:10.1182/blood.V104.11.3279.3279. ISSN 0006-4971. http://www.bloodjournal.org/content/104/11/3279.
- ↑ "Chiron and Xoma in MAb deal - Pharmaceutical industry news" (in en). The Pharma Letter. March 8, 2004. http://www.thepharmaletter.com/article/chiron-and-xoma-in-mab-deal.. Part of Xoma's 10-K filed 2004-03-15. Index page at SEC Edgar.
- ↑ "Exhibit 10.50: Agreement, dated Feb 27, 2004, by and btwn Chiron Corp and XOMA". Xoma via SEC Edgar. https://www.sec.gov/Archives/edgar/data/791908/000119312504042254/dex1050.htm.
- ↑ "Exhibit 10.2 Amended Research, Development and Commercialization Agreement". Xoma via SEC Edgar. May 26, 2005. https://www.sec.gov/Archives/edgar/data/791908/000119312505160702/dex102.htm.
- ↑ "Novartis to buy Chiron / Swiss pharmaceutical giant to pay $5.1 billion". San Francisco Chronicle. November 1, 2005. http://www.sfgate.com/business/article/Novartis-to-buy-Chiron-Swiss-pharmaceutical-2598690.php.
- ↑ "Press Release: XOMA Restructures Drug Development Collaboration Including Oncology Drug Candidate HCD122 (NASDAQ:XOMA)" (in en). Xoma. November 10, 2008. http://investors.xoma.com/releasedetail.cfm?ReleaseID=346609.
- ↑ "Lucatumumab". NCI Drug Dictionary. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI). 2011-02-02. https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=432936.
 |  |
